CN1682943A - Medicine for treating cardio-cerebral vascular disease and preparing method - Google Patents
Medicine for treating cardio-cerebral vascular disease and preparing method Download PDFInfo
- Publication number
- CN1682943A CN1682943A CN 200510053313 CN200510053313A CN1682943A CN 1682943 A CN1682943 A CN 1682943A CN 200510053313 CN200510053313 CN 200510053313 CN 200510053313 A CN200510053313 A CN 200510053313A CN 1682943 A CN1682943 A CN 1682943A
- Authority
- CN
- China
- Prior art keywords
- medicine
- cerebrovascular disease
- extractum
- add
- herba portulacae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 61
- 208000019553 vascular disease Diseases 0.000 title abstract description 4
- 229940079593 drug Drugs 0.000 title description 15
- 238000000034 method Methods 0.000 title description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 13
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 12
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 8
- 239000002798 polar solvent Substances 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 239000003208 petroleum Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 abstract description 7
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 6
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 5
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 4
- 230000000747 cardiac effect Effects 0.000 abstract description 3
- 230000002490 cerebral effect Effects 0.000 abstract description 3
- 208000019622 heart disease Diseases 0.000 abstract description 3
- 229940064064 purslane extract Drugs 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 241000700159 Rattus Species 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000001447 compensatory effect Effects 0.000 description 8
- 208000029078 coronary artery disease Diseases 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 241000219295 Portulaca Species 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000003143 atherosclerotic effect Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 208000026758 coronary atherosclerosis Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol hydrochloride Natural products C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- IROWCYIEJAOFOW-UHFFFAOYSA-N DL-Isoprenaline hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 IROWCYIEJAOFOW-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 244000234609 Portulaca oleracea Species 0.000 description 2
- 235000001855 Portulaca oleracea Nutrition 0.000 description 2
- 244000261559 Smilax china Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940039009 isoproterenol Drugs 0.000 description 2
- 229940018448 isoproterenol hydrochloride Drugs 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000002676 cerebral atherosclerosis Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 229960004604 propranolol hydrochloride Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of medicine for treating cardiac and cerebral vascular diseases and its preparation process. The medicine is prepared with purslane extract and medicinal supplementary material. The medicine is used mainly in preventing and treating heart diseases, angina pectoris, heart failure and cerebral vascular diseases caused by hyperlipemia and atherosclerosis.
Description
Technical field
The present invention relates to a kind ofly be single medicinal ingredient and have the medicine of treatment treating cardiac and cerebral vascular diseases disease and the preparation technology of this kind medicine thereof with natural drug.
Technical background
The coronary circulation obstacle causes the heart disease of myocardial ischemic injury to be called coronary heart disease.Hyperlipemia is one of main cause of disease of bringing out coronary heart disease, and atherosclerosis has then participated in the whole pathogenic process of coronary heart disease.Heart failure is that the cardiac output that multiple reason causes shrinking or diastolic dysfunction causes descends, and can not satisfy the pathological process of organism metabolism needs.Wherein by the myocardium own blood supply insufficiency due to the coronary atherosclerosis, being not only the fundamental cause that angina pectoris takes place, also is that myocardial contraction descends, the major incentive of heart failure.Therefore, blood fat reducing, prevent and treat atherosclerosis, thereby thereby the sickness rate that fundamentally prevents coronary heart disease, anginal generation to reduce heart failure has been medical circle and the key areas for paying close attention to.In recent years, the various countries scholar seeks the best by different approach and prevents and treats scheme, wherein, seeks valuable clue from traditional medicine, increases treatment means and has become the atherosclerotic a kind of important channel of treatment.The comprehensive study of Chinese medicine and national medicine becomes seeks one of atherosclerotic effective ways of treatment.
Summary of the invention
The object of the present invention is to provide a kind of is single medicinal ingredient with natural drug, hyperlipemia, atherosclerosis, coronary heart disease, angina pectoris, heart failure is had the medicine of better therapeutical effect.
Another object of the present invention is to provide the preparation method of this medicine.
The medicine of treatment cardiovascular and cerebrovascular disease of the present invention is the medicament of being made by Herba portulacae extract and pharmaceutic adjuvant.
Described Herba portulacae extract is the extractum that the herb of portulacaceous plant Herba Portulacae (Portulaca oleracea L.) obtains through water extract-alcohol precipitation.
Described Herba portulacae extract is the extractum that the herb of portulacaceous plant Herba Portulacae (Portulaca oleracea L.) obtains through water extract-alcohol precipitation after the low polar solvent reflux, extract, again.
Medicament of the present invention is to add the laggard one-step refining of adjuvant (as ultrafiltration, emulsifying, high speed centrifugation) by above-mentioned extractum, adopts made sterilization of modern medicines preparation technique or sterile preparation, liquid preparation, oral administration solid, semi-solid preparation.
Since the present invention be with single medicine as effective medicinal ingredient, so the ratio between principal agent and the adjuvant is very unimportant, be generally principal agent 40-90%, that better is 50-85%.
Technical scheme of the present invention is based on Chinese medicine and Dai Nationality's medical science to atherosclerotic pathogeny and Therapeutic Principle, with reference to the modern pharmacology achievement, according to the characteristics of medicine, extracts the pharmaceutical preparation easy to use that its effective ingredient develops.
Medicine of the present invention is mainly used in cerebrovascular disease prevention and the treatment due to heart disease, angina pectoris, heart failure and the cerebral atherosclerosis that hyperlipemia, atherosclerosis, coronary atherosclerosis cause.
Pharmaceutical dosage form of the present invention is said oral administration solid on the pharmaceutics, semi-solid preparation, oral liquid and sterilization sterile preparation.Can be the injection made of raw material of the present invention and corresponding adjuvant, tablet, granule, hard capsule, soft capsule, drop pill etc.When making different dosage forms, need to add the pharmaceutic adjuvant that adapts with it, described pharmaceutic adjuvant is the conventional pharmaceutic adjuvant of this kind dosage form, the preparation method of the amount of required adding and this kind dosage form is convention amount and conventional preparation method.
Its consumption is per day for adults 1-5g (ml), in the extractum amount.
The preparation method of the medicine of treatment cardiovascular and cerebrovascular disease of the present invention is made up of following steps:
One, get the Herba Portulacae herb and add decocting in water and carry, filter, concentrate, add ethanol, reclaim ethanol and get extractum, standby;
Two, add pharmaceutic adjuvant and the above-mentioned extractum heating for dissolving that stirs, make required dosage form.
In above-mentioned preparation method, used concentration of alcohol is 60-95%.
The preparation method of the medicine of treatment cardiovascular and cerebrovascular disease of the present invention is made up of following steps:
One, get the Herba Portulacae herb and add the low polar solvent hot reflux and extract, medicinal residues volatilize and add that ethanol is carried, filters, concentrates, added to decocting in water, recovery ethanol gets extractum behind the solvent again, and are standby;
Two, add pharmaceutic adjuvant and the above-mentioned extractum heating for dissolving that stirs, make required dosage form.
In above-mentioned preparation method, used concentration of alcohol is 60-95%, and described low polar solvent is petroleum ether, chloroform, ethyl acetate, ether, normal heptane etc.
Pharmacodynamic experiment of the present invention:
Purpose: set up the rabbit Atherosclerosis Model, observe of the effect of this medicine to atherosclerosis and blood fat reducing.In the hope of by above-mentioned test, reflect to cure mainly relevant main pharmacodynamics effect with this medicine function.
One, this medicine is to rabbit hyperlipemia, atherosclerotic influence
Experiment material:
Animal: rabbit, male and female half and half, body weight 2-2.5kg is provided by Yunnan Province natural drug pharmacology key lab.
Medicine: this medicine, 1g (ml) is equivalent to crude drug in whole 1g, is provided by Yunnan Mingyang Pharmaceutical Co., Ltd..
Be made into 4%, 8%, 12% concentration for usefulness with water, cholesterol (chemical pure) import packing is by the packing of Guangzhou Medical Depot chemical reagents corporation.
Experimental technique:
Rabbit adapts to a week under experiment condition, feed normal feedstuff and water, is divided into 5 groups at random according to blood TC and body weight, and 8 every group, sub-cage rearing.Experiment beginning back normal control group is fed normal feedstuff and water.Each dosage group and positive controls 1-6 must add hello cholesterol 0.5g (mixing in the normal feedstuff) every day in week.Add the next day that positive matched group changing every in 7-12 week and feed cholesterol 0.5g, the dosage group then gives this medicine medicinal liquid of 4%, 8%, 12% respectively, experiment finishes the weighing animal weight, on an empty stomach after 12 hours, from tame rabbit heart blood drawing 8ml, wherein 4 ml are used for separation of serum, measure following index, serum TC, Serum HDL-C, serum TG, serum LDL-C.4ml is with anticoagulant heparin in addition, and get blood 0.7ml and use NXE-1 type cone and plate viscometer under 25 ± 0.5 ℃ constant temperature, to measure its whole blood apparent viscosity at once, blood is centrifugal 10 minutes with 3000 rev/mins then, get blood plasma and survey the blood plasma apparent viscosity, open rabbit thoracic cavity careful separation aorta simultaneously to the hip arteries, its pathomorphism and carry out microscopy (JEM-1200 transmission electron microscope) detects by an unaided eye.
Conclusion:
Experimental result shows, rabbit gives TC, TG behind the cholesterol, LDL-C, HDL-C significantly raise (P＜0.01).Pathological changes appears in blood viscosity (P＜0.01) the positive controls vessel arms that rises, and normal group does not occur unusually, gives this medicine 4%, 8%, 12% and then can make above-mentioned symptom improve obviously that (TC, TG, LDL-C reduce, the HDL-C rising, and blood viscosity is normal.The speckle of blood vessel wall all significantly diminishes or disappears).Show the tangible blood fat reducing of this medicine, study of anti-atherogenic effect.
Two, this medicine is to the protection of rat heart muscle ischemia injury
Experiment material:
Animal: rat, SD, body weight 250-300g, male and female half and half are provided by Yunnan Province natural drug pharmacology key lab.
Medicine: this medicine, 1g (ml) is equivalent to crude drug in whole 1g, is provided by Yunnan Mingyang Pharmaceutical Co., Ltd..
Be made into 4%, 8%, 12% concentration for usefulness with water, the propranolol hydrochloride sheet, the 8mg/ sheet, Shanghai Xin Pa pharmaceutical Co. Ltd product is made into 0.3% concentration for using with water.Isoproterenol hydrochloride inj, 1mg/2ml, Shanghai Hefeng Pharmaceutical Co., Ltd.'s product.
Instrument: Kodak of Johnson ﹠ Johnson 750 type dry type biochemistry analyzer, the mutually beneficial company of U.S.-China.
Reagent: Kodak of Johnson ﹠ Johnson dry chemistry reagent, the mutually beneficial company of U.S.-China.
Experimental technique:
Get 60 of rats, be divided into 6 groups at random, 8 every group, male and female half and half are established normal control group (N), feedwater; Model control group (C): feedwater; The basic, normal, high dosage group of this medicine (L, M, H), give this medicine medicinal liquid of 4%, 8%, 12% respectively: positive controls (S), give 0.3% Propranolol medicinal liquid.Each is organized all by 20ml/kg (ig) administration, once a day, and continuous 6 days.In administration the 5th day, N organized to NS4ml/kg (SC), gave isoproterenol hydrochloride inj (1mg/2ml) 4ml/kg (SC), repeated above-mentioned administration after 24 hours for all the other 5 groups.1h after giving isoproterenol the 2nd time use etherization with rat, and the eye socket rear vein beard is got blood, and separation of serum is surveyed creatine kinase (CPK) activity (enzyme process).
Conclusion:
Isoproterenol 2mg/kg (SC) can make that rat blood serum CPK is active and obviously rise that (P＜0.001=shows and causes the rat heart muscle ischemia model; can make the active obviously decline (P＜0.05) of rats with myocardial ischemia serum CPK and give this medicine 1.01g/kg, show that this medicine has protective effect to the rat heart muscle ischemia injury.
Three, this medicine is to the protection of rabbit heart failure damage
Experiment material:
Animal: rabbit, male and female half and half, body weight 2-2.5kg is provided by Yunnan Province natural drug pharmacology key lab.
Medicine: this medicine, 1g (ml) is equivalent to crude drug in whole 1g, is provided by Yunnan Mingyang Pharmaceutical Co., Ltd..
Be made into 12% concentration for usefulness, 0.9% NS 5ml/kg with water for injection
Instrument: SJ-II type physiograph
Experimental technique:
This medicine of administration group intravenous injection 200ml/kg, matched group injection equivalent NS, 0.5h after, from the quick blood-letting of femoral artery to arteriotony is 40mmHg, blood pressure gos up, need blood-letting once more, until blood pressure drops when having only an amount of blood of feedback to keep 40mmHg for losing the compensatory phase, the time from blood-letting first to the compensatory beginning of mistake is the compensatory time.Total blood volume of being emitted in compensatory process is maximum blood loss.After the appearance mistake is compensatory, the blood of being emitted is failed back in femoral vein immediately, continued to observe 2 hours, write down the compensatory time, 1-2 hour blood pressure level is declared the curative effect of medication that continues behind maximum blood loss and the feedback blood, the results are shown in Table 3-1.
| Matched group | Experimental group | |
| Compensatory time minute | 24±15 | ?46±18 ** |
| Maximum blood loss ml/kg | 23±4 | ?33±3.4 *** |
| Blood transfusion back blood pressure 1 hour | 77±6 | ?81±21 * |
| Blood transfusion back blood pressure 2 hours | 75±7.65 | ?89±15.4 ** |
*P＞0.05??
**P＜0.05??
***P＜0.01
Conclusion:
Experimental result shows: Herba Portulacae obviously prolongs the compensatory time, and maximum blood loss is more than matched group, and 2 hours blood pressure is apparently higher than matched group behind the feedback blood.
Four, this medicine is to the rat long term toxicity test
This medicine is irritated stomach with 1.2g/kg, 4.5g/kg and 9g/kg dosage (being equivalent to 8 times, 30 times and 60 times with dosage of the clinical day for human beings according to the weight) and is given rat, once a day, continuous 45 days, big mouse cage look on examine no abnormal, body weight gain is normal, hematology and blood biochemical are learned index, and the main organs coefficient is all in normal range.The high dose group rat heart, liver, spleen, lung, kidney, thyroid, thymus, adrenal gland, stomach and the histological examination of duodenum pathology show no obvious abnormalities.
The specific embodiment
Embodiment 1:
Get 40 parts of Herba Portulacaes and add 6 times of water gagings and boil and carry twice, each 2 hours, filter, concentrating under reduced pressure, add ethanol and make and contain the alcohol amount and reach 70% and left standstill 24 hours, supernatant reclaims ethanol and gets extractum, and is standby; Get 50 parts of PEG6000 (polyethylene glycol 6000) and the aforementioned extractum heating for dissolving that stirs, make drop pill with common process.
Embodiment 2:
Get 40 parts of Herba Portulacaes and add low polar solvent (as petroleum ether etc.) submergence medical material boiling temperature reflux 2 hours, reclaim solvent, adding 6 times of water gagings after medical material volatilizes again boils and carries twice, each 2 hours, filtration, concentrating under reduced pressure, add ethanol and make and contain the alcohol amount and reach 70% and left standstill 24 hours, supernatant reclaims ethanol and gets extractum, and is standby; Get that 1 part of 10 parts of starch, 6 parts in dextrin, Pulvis Talci mix with aforementioned extractum, granulation, drying, technology is made tablet routinely.
Embodiment 3:
Get 40 parts of Herba Portulacaes and make extractum by above-mentioned technology, standby; Get that 10 parts in syrup mixes with aforementioned extractum, sterilization filling routinely technology make oral liquid.
Embodiment 4:
Get 40 parts of Herba Portulacaes and make extractum by above-mentioned technology, standby; Get 10 parts of vegetable oils and aforementioned extractum behind emulsifying process routinely technology make soft capsule.
Embodiment 5:
Get 5 parts of Herba Portulacaes and make extractum by above-mentioned technology, standby; Get Tween 80 and add water for injection in right amount and mix back ultrafiltration (filter press for 0.1-0.25MPa) with aforementioned extractum, make injection after the technology sterilization routinely.
Embodiment 6:
Get 4 parts of Herba Portulacaes and make extractum by above-mentioned technology, standby; Get that 1 part of 2 parts of starch, dextrin mix with aforementioned extractum, after the drying routinely technology make hard capsule.
Claims (8)
1, a kind of medicine for the treatment of cardiovascular and cerebrovascular disease is characterized in that it being the medicament of being made by Herba portulacae extract and pharmaceutic adjuvant.
2,, it is characterized in that described Herba portulacae extract is the extractum that the herb of portulacaceous plant Herba Portulacae obtains through water extract-alcohol precipitation according to the medicine of the described treatment cardiovascular and cerebrovascular disease of claim 1.
3,, it is characterized in that described Herba portulacae extract is the extractum that the herb of portulacaceous plant Herba Portulacae obtains through water extract-alcohol precipitation again after the low polar solvent reflux, extract, according to the medicine of the described treatment cardiovascular and cerebrovascular disease of claim 1.
4, according to the preparation method of the medicine of the described treatment cardiovascular and cerebrovascular disease of claim 1, it is characterized in that forming by following steps:
One, get the Herba Portulacae herb and add decocting in water and carry, filter, concentrate, add ethanol, reclaim ethanol and get extractum, standby;
Two, add pharmaceutic adjuvant and the above-mentioned extractum heating for dissolving that stirs, make required dosage form.
5, according to the preparation method of the medicine of the described treatment cardiovascular and cerebrovascular disease of claim 4, it is characterized in that used concentration of alcohol is 60-95%.
6, according to the preparation method of the medicine of the described treatment cardiovascular and cerebrovascular disease of claim 1, it is characterized in that forming by following steps:
One, get the Herba Portulacae herb and add the low polar solvent hot reflux and extract, medicinal residues volatilize and add that ethanol is carried, filters, concentrates, added to decocting in water, recovery ethanol gets extractum behind the solvent again, and are standby;
Two, add pharmaceutic adjuvant and the above-mentioned extractum heating for dissolving that stirs, make required dosage form.
7, according to the preparation method of the medicine of the described treatment cardiovascular and cerebrovascular disease of claim 6, it is characterized in that used concentration of alcohol is 60-95%.
8, according to the preparation method of the medicine of the described treatment cardiovascular and cerebrovascular disease of claim 6, it is characterized in that described low polar solvent is petroleum ether, chloroform, ethyl acetate, ether, normal heptane.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510053313 CN1682943A (en) | 2005-02-23 | 2005-02-23 | Medicine for treating cardio-cerebral vascular disease and preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510053313 CN1682943A (en) | 2005-02-23 | 2005-02-23 | Medicine for treating cardio-cerebral vascular disease and preparing method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1682943A true CN1682943A (en) | 2005-10-19 |
Family
ID=35262562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510053313 Pending CN1682943A (en) | 2005-02-23 | 2005-02-23 | Medicine for treating cardio-cerebral vascular disease and preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1682943A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111481594A (en) * | 2019-01-25 | 2020-08-04 | 大江生医股份有限公司 | Plant fermented product and its use for regulating gene expression and cardiovascular health |
-
2005
- 2005-02-23 CN CN 200510053313 patent/CN1682943A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111481594A (en) * | 2019-01-25 | 2020-08-04 | 大江生医股份有限公司 | Plant fermented product and its use for regulating gene expression and cardiovascular health |
| CN111481594B (en) * | 2019-01-25 | 2022-03-08 | 大江生医股份有限公司 | Plant fermented product and its use for regulating gene expression and cardiovascular health |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1241574C (en) | Medicine for relieving spasm and pain and preparation process thereof | |
| CN1172677C (en) | Application of astragaloside IV in preparation of pharmaceutical composition | |
| CN1206236C (en) | Manyprickle acanthopanax general saponin extractive and its medicinal composition | |
| CN1682943A (en) | Medicine for treating cardio-cerebral vascular disease and preparing method | |
| CN1291735C (en) | A traditional Chinese medicine dripping pill preparation for promoting blood circulation, removing blood stasis, promoting qi and relieving pain | |
| CN101033245A (en) | Preparation method and application of pedunculoside | |
| CN1682942A (en) | Medicine for treating cardio-cerebral vascular diseases and preparing method | |
| CN1282467C (en) | Medicine for treating coronary disease and stenocardia and its preparation method | |
| CN1582952A (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN1698717B (en) | Chinese medicinal compound fat emulsion injection and its preparation method | |
| CN1168462C (en) | An oral solution capable of lowering blood fat and improving symptoms of myocardial ischemia and myocardial infarction | |
| CN100343266C (en) | Picrorhiza total glycoside extract and its application in preparation of liver disease medicine and preparation method | |
| CN1292769C (en) | Chinese medicine for preventing and treating atherosclerosis and its preparing method | |
| CN101632829B (en) | Anti-hepatofibrosis traditional Chinese medicament composition, preparation method thereof and medicament preparation | |
| CN1150918C (en) | Medicine containing active components of Panax japonicum root and preparing process thereof | |
| CN1251745C (en) | Medicine for treating liver and biliary diseases and its preparing method | |
| CN1488395A (en) | Java brucea oil-emulsion injecta with low-toxicity and preparing method thereof | |
| CN1258365C (en) | Pharmacetutical composition for treating cardiovascular and cerebrovascular disease and its preparing process | |
| CN1176648C (en) | Soft capsule in total flavone of hawthorn leaves and its preparing method | |
| CN1239159C (en) | Medicine composition for reducing blood fat | |
| CN1241559C (en) | A kind of traditional Chinese medicine hypoglycemic agent and preparation method thereof | |
| CN1939382A (en) | Chinese-medicinal composition for treating coronary heart disease and its preparation | |
| CN1267126C (en) | Chinese medicine for treating coronary heart disease and angina pectoris | |
| CN101032534A (en) | Method of preparing jiubiying total saponins and the application thereof | |
| CN1118278C (en) | Application of ursolic acid in medicine for treating viral hepatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |